4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
Gene Therapy Promise | Explore 4D Molecular Therapeutics' innovative approach to treating wet AMD and DME, with Phase 3 trials for 4D-150 set to begin in 2025 |
Market Dynamics | Delve into the $2 billion wet AMD market opportunity and the challenges of treatment durability that could narrow the addressable patient population |
Financial Outlook | Analyst price targets range from $15 to $45, reflecting diverse views on 4DMT's potential amid ongoing R&D investments and negative earnings |
Competitive Edge | Learn how 4DMT's clinically validated gene therapy platform positions the company in a crowded field, with potential for expansion beyond ophthalmology |
Metrics to compare | FDMT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFDMTPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.5x | −4.0x | −0.5x | |
PEG Ratio | 0.05 | −0.03 | 0.00 | |
Price/Book | 0.6x | 0.9x | 2.6x | |
Price / LTM Sales | 11,540.9x | 48.7x | 3.3x | |
Upside (Analyst Target) | - | 108.7% | 43.5% | |
Fair Value Upside | Unlock | 11.4% | 6.9% | Unlock |